Background. The ability of follow-up imaging examinations to predict treatment failure in patients with spine infections has not been well studied.
involving epidural abscesses [2] [3] [4] . Follow-up imaging, via MRI or CT, has been widely used to monitor patients' response to therapy in the modern era, at significant cost and undetermined benefit.
There are scarce published data on the ability of follow-up imaging examinations to predict treatment failure in patients with spine infection. Carragee [5] reported the results of follow-up MRIs for 16 patients with pyogenic spine infections using a grading system that incorporated both bony and soft-tissue changes. Of 8 patients who underwent MRI within 6 weeks after starting conservative therapy, 7 had findings that were considered to be worse. Three patients subsequently underwent surgery, at least in part because of the MRI findings, but intraoperative findings and cultures did not suggest uncontrolled infection. Accordingly, the author recommended caution in interpreting follow-up MRI findings, noting that the significance of worsening MRI findings in the face of clinical improvement is unclear.
Other small studies of MRI findings for patients with spine infection have reported a reduction in abnormal soft-tissue enhancement as the first sign of resolution on follow-up MRIs [6] [7] [8] . Bone and disk space were variably improved, were equivocal, or appeared worse. These findings further support the evaluation of soft-tissue findings, not bony changes, as the basis for determining therapeutic response.
In this study, we aimed to determine whether applying a simple grading system focused on soft-tissue findings for follow-up imaging results 4-8 weeks after initiation of therapy in patients with spine infection provides clinically useful prognostic information.
METHODS

Study design.
After receiving approval from our institutional review board, we conducted a single-center, retrospective cohort study. All potential cases of native spine infection (diskspace infection, vertebral osteomyelitis, and epidural abscess) that occurred during 1994-2002 were reviewed after searching the Mayo Clinic Medical and Surgical Indexes [9] , a radiologic database, and a microbiology database for related terms. Two hundred sixty-five patients met the strict case definitions outlined below. Of those patients, 79 patients aged у18 years who had spine infection and who had available baseline and 4-8-week follow-up MRI reports were included in the study. Patients with tuberculous or brucellosis were excluded, as were patients who had spinal instrumentation present at the time of diagnosis. We performed detailed abstraction of clinical data, management strategies, and outcome from the inpatient and outpatient medical record using a coded data collection instrument. Medical and surgical diagnostic approaches and therapies were not standardized and were performed at the discretion of the treating physicians.
Definitions. Definitions were determined before data collection and are summarized in table 1. An infectious diseases physician assigned grades of "improved," "equivocal," or "worse" on the basis of interval changes in the paraspinal musculature, psoas musculature, and epidural space, compared with baseline findings, by reviewing the neuroradiologists' initially reported interpretations and comparisons performed as part of routine clinical practice (table 1) . Because of difficulties clearly delineating the distinction between epidural enhancement, phlegmon, and definite abscess, we used a broad definition of epidural involvement (i.e., the presence of any of these findings), which is similar to strategies used by others [10, 11] .
Statistical analysis. For comparisons between imaging findings and demographic and clinical factors, the 2-sample t test was used for continuous variables, and the x 2 test was used for categorical variables, as appropriate. Kaplan-Meier survival methods and the log rank test were used to analyze clinical and microbiologic failure by scan results. Because initial surgical management of the spinal infection may have acted as a confounding variable on the follow-up imaging results and outcome, we also performed a survival analysis that excluded patients who were initially treated surgically. To assess the potential impact of referral bias, we compared whether patients who had been transferred from outside institutions well into their treatment courses differed with regard to MRI findings and microbiologic treatment failure by use of contingency tables and the x 2 test. Finally, to assess for selection bias, we compared our cohort with respect to demographic factors, clinical factors, and outcomes of patients with spine infection who were evaluated at our institution during the study period with those who did not undergo 4-8-week follow-up imaging examinations using the 2-sample t test and the x 2 test as indicated. A P value of р.05 was to be considered statistically significant. Data were analyzed using JMP software, version 5.1.2 (SAS Institute).
RESULTS
Seventy-nine patients were included in the study. The median duration of follow-up for patients who did not experience treatment failure was 730 days (range, 21-3996 days). Demographic information is shown in table 2. Clinical and microbiologic characteristics of the cohort are shown in table 3. Twenty-two patients (28%) were presumed to have postprocedural infection (e.g., infection after discectomy, laminectomy, epidural injections, etc.) on the basis of a recent history of invasive spinal procedures that had occurred a median of 41 days (range, 5-265 days) before diagnosis. The duration of effective parenteral and total antimicrobial therapy is shown in table 3. Only 4 patients received !4 weeks of parenteral therapy; in 3 patients, highly bioavailable oral antimicrobials were used instead, and in the fourth patient, severe antimicrobial-related adverse effects prompted cessation of parenteral therapy after 24 days.
The overall grade assigned to each follow-up image, stratified by clinical status, is shown in table 4. None of the 27 patients who demonstrated improvement on follow-up images developed microbiologic failure, compared with 5 (13%) of 38 patients with equivocal follow-up imaging findings and 4 (29%) of 14 patients whose follow-up imaging findings worsened. At least in part in response to the imaging findings, 14 patients subsequently underwent an invasive procedure. Three of these 14 patients were eventually confirmed to have experienced microbiologic treatment failure, and an additional 5 patients were given a diagnosis of clinical treatment failure in the absence of microbiologic confirmation.
A univariate analysis of demographic, microbiologic, clinical, and management variables associated with improved versus equivocal or worse follow-up imaging findings is shown in table 5. A number of variables assessed before performance of followup imaging were associated with improvement on the followup MRI examination. Twenty-six (96%) of 27 patients with improvement in the imaging findings also experienced clinical improvement at follow-up, compared with 26 (50%) of 52 patients who had equivocal or worse follow-up imaging findings ( ). Twenty-five (93%) of 27 patients with improved P ! .001 follow-up imaging findings had evidence of epidural space involvement at baseline, compared with 36 (69%) of 52 of those with unimproved findings ( ); perhaps this was related P p .02 to the way in which the scans were graded. Only 1 (4%) of 27 patients with improved imaging findings initially had a psoas abscess, compared with 10 (19%) of 52 patients with unimproved findings ( ). P p .09 Of the variables assessed that may have been influenced by follow-up imaging findings (i.e., outcomes and management decisions that occurred temporally after follow-up imaging), the need for unexpected surgery was more commonly seen among patients with imaging findings that were equivocal or worse (table 5) . One (4%) of 27 patients with improved findings underwent an unplanned surgical procedure on the spine, compared with 15 (29%) of 52 patients with equivocal or worse imaging findings ( ). P p .008 Kaplan-Meier survival curves for microbiologic and clinical treatment failure, by follow-up imaging findings, are shown in figure 1 . The estimated 1-year rates of survival free of microbiologically confirmed failure were 100%, 89% (95% CI, 74%-96%), and 56% (95% CI, 24%-83%) for improved, equivocal, and worse follow-up imaging findings, respectively ( ). P p .004 The estimated 1-year rates of survival free of clinical failure were 100%, 78% (95% CI, 62%-89%), and 29% (95% CI, 11%-56%) for improved, equivocal, and worse follow-up imaging findings, respectively ( ). When we excluded patients who were P ! .001 initially treated surgically from the analysis, the estimated 1-year rates of survival free of microbiologically confirmed failure were 100%, 87% (95% CI, 66%-96%), and 54% (95% CI, 19%-85%) for improved, equivocal, and worse follow-up imaging findings, respectively ( ). The causative pathogens in the 9 patients P p .03 who developed microbiologic treatment failure were Staphylococcus aureus (6 patients), Streptococcus agalactiae (2 patients), and a polymicrobial infection with viridans group streptococci and Neisseria species (1 patient).
Clinical status at follow-up was improved in 52 patients (66%), equivocal in 19 patients (24%), and worse in 8 patients (10%). Three (6%) of 52 patients who had clinical improvement at follow-up developed microbiologic treatment failure, compared with 4 (21%) of 19 patients who had equivocal clinical status and 2 (25%) of 8 patients who had worse clinical status. Of the 3 patients who experienced clinical improvement and who developed microbiologic treatment failure, 2 had markedly elevated levels of inflammatory biomarkers during the 4-8-week follow-up period, identifying them as high risk for failure. The third patient did not have levels of inflammatory biomarkers determined during follow-up. This patient was infected with S. aureus and initially responded to 6 weeks of parenteral antimicrobial therapy. Four weeks after treatment was stopped, the patient developed S. aureus septic arthritis with bacteremia. Another MRI of the spine was performed at that time; the findings were interpreted as being consistent with residual infection, and the patient was treated with a second prolonged course of parenteral antimicrobials. Spine-specific cultures were not performed to document persistent spinal infection. A flow chart demonstrating the clinical status, follow- up inflammatory biomarker results, and outcomes is shown in figure 2 .
To assess for referral bias in MRI findings and microbiologic treatment failure, we compared MRI findings between patients who were referred from outside institutions well into their treatment courses with the remainder of the cohort. Six (24%), 12 (48%), and 7 (28%) of patients in the referral group and 21 (39%), 26 (48%), and 7 (13%) of the patients in the remaining cohort had improved, equivocal, or worse MRI findings (P p .19). Four (16%) of 25 patients in the referral group and 5 (9%) of 54 patients in the remaining cohort developed microbiologic failure ( ). To assess for selection bias, we com-P p .38 pared the cohort of patients included in this study with 186 patients seen at our institution during the study period whose cases met our case definition but who did not have 4-8-week follow-up imaging performed. Between our cohort and the comparator group that did not have 4-8-week imaging performed, there were no significant differences in age at diagnosis ( ), case definition status ( ), presence of psoas P p .82 P p .44 abscesses ( ), presence of neurologic deficit at diagnosis P p .39 ( ), or the development of microbiologic ( ) or P p .25 P p .50 clinical ( ) treatment failure. Patients in our cohort were P p .50 more likely to be female ( ) and to have epidural in-P p .03 volvement ( ) than were patients who did not have fol-P ! .001 low-up MRI performed.
DISCUSSION
This study shows that application of a simple grading scale to follow-up images 4-8 weeks after the diagnosis and treatment of spine infection conveys useful prognostic information regarding treatment failure risk. Furthermore, we suggest that patients' 4-8-week clinical statuses and inflammatory biomarker responses are helpful as cost-conscious initial screenings to determine which patients are at risk for treatment failure and may benefit from additional imaging.
The increasingly common practice of medically managing serious spine infections-particularly epidural abscesses-represents a dramatic shift from the historical teaching that the diagnosis of epidural abscess constitutes a neurosurgical emergency [12] . Clinicians faced with the challenging task of conservatively treating older, frail patients with spine infection have come to rely on the increasingly available technology of MRI and CT examinations as an aid. MRI is unquestionably the diagnostic test of choice for spine infections [13] , but the clinical utility of performing follow-up MRI has been questioned [5, 7] . Carragee [5] reported no clear association between MRI findings and patients' clinical status and outcome. Furthermore, that report suggested that surgeries may have been unnecessarily performed because of the MRI results. To our knowledge, this is the first published study to demonstrate the prognostic utility of serial MRIs in stratifying patients' risk of failure.
Although long accepted as clinical dogma, the accuracy with which serial inflammatory biomarkers predict clinical outcomes in osteomyelitis has not been well described in the published literature [14] . Carragee et al. [14] reported that a 25% decrease in the erythrocyte sedimentation rate in the first month of treatment for vertebral osteomyelitis was rarely associated with treatment failure. However, the majority of patients who did not have improved erythrocyte sedimentation rates did not experience treatment failure, highlighting the poor specificity of this test. Similarly, most patients with either equivocal or worse-appearing follow-up imaging findings did not develop microbiologic treatment failure. Furthermore, as shown in figure 2, all patients but 1 in our cohort who developed failure would have been identified using a simple algorithm. Therefore, although follow-up imaging studies apparently do convey helpful prognostic information, a more cost-effective approach may be to first identify patients at risk of failure by clinical status and inflammatory biomarker response, and then to order imaging examinations for those patients who are deemed to be at high risk. Such an approach may eliminate unnecessary costs, patient discomfort associated with the examinations, and unnecessary invasive procedures in low-risk patients.
It is interesting that clinical failure in the absence of micro- biologic confirmation was diagnosed in 11 patients (21%) with unimproved follow-up imaging findings but in no patients with improved follow-up imaging findings. This discrepancy is likely a direct result of physicians basing the clinical diagnosis of failure at least in part on follow-up imaging findings. In 5 of the 11 patients, no attempts were made to culture an organism to corroborate the clinical suspicion of treatment failure. In the other 6 patients, cultures were attempted, and the results were negative, but the patients were re-treated on the basis of clinical suspicion of relapsed infection. Thus, the Kaplan-Meier survival curves estimating cumulative incidence of clinical failure by imaging status greatly overestimate "true" clinical failure, because equivocal and worse imaging findings almost certainly bias clinicians toward the diagnosis of treatment failure. Unlike Carragee's [5] previously reported method of grading follow-up images, our method relies only on soft-tissue findings. The association between having epidural involvement at baseline and having an improved follow-up MRI is likely, in part, a function of our grading system; patients with epidural involvement at baseline had the opportunity to show improvement on follow-up images. We stress that the findings of this study may not be applicable to patients who undergo followup imaging examinations outside of the time period we studied. In our experience, and consistent with the results of Carragee's study [5] , the findings of imaging studies performed !4 weeks after diagnosis and commencement of treatment are more likely to appear unimproved or worse and, thus, may overestimate the risk of treatment failure outlined in this study.
Our results may differ from the results of other studies for a number of reasons. First, we limited our assessment of followup images to soft-tissue findings. Prior studies detailing the evolution of findings on follow-up MRI examinations in patients with spine infections suggested that bone and disk space findings may worsen in spite of clinical improvement of the patient, whereas soft-tissue findings tended to improve [6] . Second, in other reports, MRIs were performed over a wider range of times after diagnosis-sometimes in the early weeks after diagnosis, when examination findings may be more likely to lag [5, 6] . All imaging data included in our study were obtained during the clinically relevant period of 4-8 weeks after diagnosis and treatment of spine infection. During this time, clinicians must decide whether to prolong antimicrobial therapy either parenterally or orally, to stop antimicrobial therapy, or to proceed with other diagnostic or therapeutic measures that may be invasive. Furthermore, clinicians must try to discern whether patients with persistent pain have residual active infection or musculoskeletal pain sequelae of an adequately treated infection. MRI results commonly guide these decisions.
The study has a number of strengths. It is the largest study of follow-up imaging examinations of cases of spine infection, and it is supported with abundant clinical details. Definitions were employed before data collection and were rigorously observed. The grading scale is simple and easily applied. Excellent follow-up of successfully treated patients limits the likelihood that failure events were underestimated.
Our study has several limitations inherent to its retrospective design. The Mayo Clinic (Rochester, MN) is a tertiary referral center, which means there is a risk of referral bias. However, we recorded whether patients were transferred from other hospitals well into their treatment course, and we found no significant differences in MRI findings or microbiologic failure between groups. Our cohort was at risk of selection bias. Patients with 4-8-week follow-up imaging data may be at higher risk than are those for whom imaging examinations were not performed. Patients who underwent follow-up imaging were more likely to have epidural involvement as we broadly defined it. It is likely that clinicians believed that these patients were at higher risk and, therefore, performed follow-up imaging studies. However, there were no differences in clinical or microbiologic failure rates between our cohort and patients who did not have 4-8-week imaging examinations performed. Follow-up imaging examinations were interpreted by neuroradiologists as part of routine patient care. Neuroradiologists may not commonly interpret imaging examinations elsewhere, but the simplicity of the grading scale minimizes this concern. Instances of incomplete laboratory and clinical data were unavoidable, given the retrospective design (i.e., not all patients had inflammatory biomarker data available for review during the 4-8-week follow-up period). Patients with equivocal or worse follow-up imaging findings may have received a more intensive evaluation for treatment failure from treating clinicians than did patients with improved findings, inflating the diagnosis of treatment failure. However, microbiologic failure, as evidenced by persistently positive culture results, is the sine qua non of true treatment failure, and we expect that patients with this finding would have come to clinical attention.
In summary, spinal infections are often disabling and are occasionally catastrophic. Management is increasingly nonsurgical, so clinicians face a pressing need for accurate tests to facilitate appropriate management decisions. We suggest that 4-8-week follow-up clinical status, inflammatory biomarkers, and, for selected patients, a simple grading scale applied to follow-up MRI findings could be used to stratify patients' risk of failure. Prospective studies to validate the clinical efficacy and cost-effectiveness of this approach are warranted.
